BTIG Maintains a Buy Rating on Transenterix Inc (NYSEMKT:TRXC)

In a report released today, Sean Lavin from BTIG maintained a Buy rating on Transenterix Inc (NYSEMKT: TRXC), with a price target of $6. The company’s shares closed yesterday at $2.80.

Transenterix Inc has an analyst consensus of Strong Buy.

The company has a one year high of $4.87 and a one year low of $1.40. Currently, Transenterix Inc has an average volume of 538.6k.

According to TipRanks.com, Lavin is a 2-star analyst with an average return of -0.2% and a 44.1% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Trivascular Technologies, Boston Scientific Corp., and Varian Medical Systems.

TransEnterix Inc is a medical device company engaged in the development and commercialization of a robotic assisted surgical system called the SurgiBot System.